Nyxoah (NYXH) Fundamentals 2026 — Revenue Analysis | SniperIQ

.50 on the NASDAQ. This SniperIQ fundamentals page covers Nyxoah's valuation, profitability (net margin -527.8%), revenue (€10M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Nyxoah's market cap?

Nyxoah (NYXH) has a market capitalization of approximately $60M, trading at

.50 on the NASDAQ. Market cap moves with the live share price.

What is Nyxoah's P/E ratio?

Nyxoah's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Nyxoah?

Nyxoah runs a net profit margin of -527.8%, a gross margin of 48.3%, and an operating margin of -527.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Nyxoah generate?

Nyxoah reported revenue of €10M for fiscal year 2025, with net income of -€90M and earnings per share (EPS) of -2.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Nyxoah pay a dividend?

Nyxoah does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Nyxoah financially healthy?

Nyxoah carries a debt-to-equity ratio of 1.01x and a current ratio of 0.99x, with a market beta of 0.96. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Nyxoah a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nyxoah (NYXH) the key facts are: market cap $60M, revenue €10M, 52-week range 1.26-8.588. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.